Premera Bluecross oral iron chelators Coverage Update

Coverage Criteria for Oral Iron Chelators

Generic deferasirox — transfusional hemosiderosis (transfusion-dependent)

Covered when ALL of the following are met

Generic deferasirox transfusional criteria: The individual is receiving blood transfusions at regular intervals.

Serum ferritin threshold: Prior to starting deferasirox, the individual's serum ferritin level is > 1,000 micrograms/liter.> 1,000 mcg/L

Prescribing clinician: Deferasirox is prescribed by or in consultation with a hematologist.

Generic deferasirox — non-transfusion dependent thalassemia (NTDT)

Covered when ALL of the following are met

Age requirement: The individual is aged 10 years or older.

Age based on FDA labeling and trial enrollment.

Serum ferritin threshold: Prior to starting deferasirox, the individual's serum ferritin level is > 300 micrograms/liter.> 300 mcg/L

Two consecutive values ≥14 days apart required per trial-based criteria (see indication-specific efficacy criteria).

Prescribing clinician: Deferasirox is prescribed by or in consultation with a hematologist.

Exjade / Jadenu / Jadenu Sprinkle (branded deferasirox) — transfusional hemosiderosis

Covered when ALL of the following are met

Transfusion requirement: The individual is receiving blood transfusions at regular intervals.

Serum ferritin threshold: Prior to starting Exjade, Jadenu, or Jadenu Sprinkle, the individual's serum ferritin level is > 1,000 micrograms/liter.> 1,000 mcg/L

Prescribing clinician: Exjade, Jadenu, or Jadenu Sprinkle is prescribed by or in consultation with a hematologist.

Generic trial or intolerance: Has tried generic deferasirox and had an inadequate response after 3 months of treatment or had intolerance to generic deferasirox.

Exjade / Jadenu / Jadenu Sprinkle — NTDT

Covered when ALL of the following are met

Age requirement: The individual is aged 10 years or older.

Serum ferritin threshold: Prior to starting Exjade, Jadenu, or Jadenu Sprinkle, the individual's serum ferritin level is > 300 micrograms/liter.> 300 mcg/L

Prescribing clinician: Exjade, Jadenu, or Jadenu Sprinkle is prescribed by or in consultation with a hematologist.

Generic trial or intolerance: Has tried generic deferasirox and had an inadequate response after 3 months of treatment or had intolerance to generic deferasirox.3 months trial

Generic deferiprone (deferiprone) — transfusional iron overload due to thalassemia syndromes

Covered when ALL of the following are met

Age requirement: The individual is aged 3 years or older.

Serum ferritin threshold: Prior to starting deferiprone, the individual's serum ferritin level was > 2,500 micrograms/liter.> 2,500 mcg/L

This threshold is used in pooled analyses to define prior chelation failure.

Prescribing clinician: Deferiprone is prescribed by or in consultation with a hematologist.

Generic deferiprone — adult dependent thalassemia criteria (alternate age rule)

Covered when ALL of the following are met

Age requirement (alternate wording): The individual is aged 18 years or older.

Policy includes alternate age-based criteria in some sections; see prescribing information and policy history.

Serum ferritin threshold: Prior to starting deferiprone, the individual's serum ferritin level was > 300 micrograms/liter.> 300 mcg/L

Prescribing clinician: Deferiprone is prescribed by or in consultation with a hematologist.

Ferriprox (branded deferiprone) — thalassemia/transfusion indications

Covered when ALL of the following are met

Age requirement: For transfusional thalassemia indications, the individual is aged 3 years or older.

Serum ferritin threshold: Prior to starting Ferriprox, the individual's serum ferritin level was > 2,500 micrograms/liter (or other indication-specific thresholds as noted in policy).> 2,500 mcg/L

Branded product criteria reference indication-specific thresholds in the policy.

Generic trial or intolerance: Has tried generic deferiprone and had an inadequate response after 3 months of treatment or had intolerance to generic deferiprone.3 months trial

Coverage of Ferriprox requires prior trial of generic deferiprone unless intolerance documented.

Indication-specific efficacy criteria — Covered when supported by clinical trial eligibility criteria and indication-specific requirements

Covered when supported by clinical trial eligibility criteria and indication-specific requirements

NTDT Study 5 eligibility and dosing: Patients ≥10 years with LIC ≥5 mg Fe/g dw by R2 MRI and serum ferritin >300 mcg/L (two consecutive values ≥14 days apart); doses studied 5 or 10 mg/kg/day with option to increase after 6 months if LIC >7 mg Fe/g dw and LIC reduction <15%; target LIC <5 mg Fe/g dw.LIC ≥5 mg Fe/g dw; ferritin >300 mcg/L

Efficacy: dose effect favoring 10 mg/kg/day; target attainment rates reported in trial.

Study 6 starting-dose rules: Starting doses assigned by LIC: 20 mg/kg/day if LIC >15 mg Fe/g dw, 10 mg/kg/day if LIC 3–15 mg Fe/g dw, observation if LIC <3 mg Fe/g dw; doses may be increased to a maximum (study-defined) after 6 months if LIC >7 mg Fe/g dw and LIC reduction <15%.LIC thresholds at 3, 5, 7, 15 mg Fe/g dw

Primary endpoint in Study 6 was proportion achieving LIC <5 mg Fe/g dw.

All uses of the medications that are not specifically described in this policy are considered investigational. Coverage decisions will be limited to the indications and criteria enumerated in this document; requests for treatment of other conditions will be denied as investigational unless and until supported by applicable policy revisions or other authoritative coverage guidance.

This medical policy does not apply to Medicare Advantage. Coverage is subject to the limits and conditions of the member's benefit plan; providers and members must consult the member benefit booklet or contact customer service to determine whether any benefit limitations apply.

Use of iron chelators under this policy requires appropriate safety monitoring aligned with product labeling. Known serious risks include agranulocytosis with deferiprone and dose‑related increases in serum creatinine and gastrointestinal adverse events with deferasirox; these and other safety concerns must be managed per the prescribing information. Use of these agents without monitoring or where safety risks are unmanaged (for example, untreated creatinine elevation or lack of neutrophil monitoring) may be considered not medically necessary and will be excluded from coverage.

Providers should prescribe and monitor therapy in consultation with a hematologist when indicated and supply documentation (office notes, laboratory monitoring) showing that safety parameters recommended in the FDA‑approved labeling are being followed during authorization and at re‑authorization.

Coding and Thresholds

Serum ferritin thresholds — indication-specific

Transfusional (transfusion-dependent)Serum ferritin > 1,000 mcg/L prior to starting deferasirox (generic and branded transfusional criteria).

NTDT (non–transfusion dependent thalassemia, age ≥10)Serum ferritin > 300 mcg/L prior to starting deferasirox (Study 5 and policy NTDT criteria).

Deferiprone (transfusional references)Pooled and trial references cite serum ferritin thresholds up to > 2,500 mcg/L for some deferiprone transfusional indications or as a failure criterion.

LIC threshold and targets

Study 5 eligibility (NTDT)Liver iron concentration (LIC) ≥ 5 mg Fe/g dry weight measured by R2 MRI required for enrollment.

Target LICPrimary goal in trials: reduce LIC to < 5 mg Fe/g dw (target reached by a proportion of treated patients).

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior authorization and duration

Prior authorization is required for drugs listed in this policy. Initial and re-authorization reviews, including non-formulary exception requests, may be approved up to 12 months when the drug-specific coverage criteria are met. Non-formulary exception authorizations may be approved for up to 12 months.

Initial and re-authorization reviews may be approved up to 12 months when drug-specific coverage criteria are met.
Non-formulary exception reviews may be approved up to 12 months.

Documentation Required

Required documentation and denial risk

Medical records submitted must document that the medical necessity criteria are met. Lack of documentation may lead to denial.

Include office visit notes with diagnosis, serum ferritin levels, and medication history.

Initial Therapy Criteria and Clinical Guidance

Initial therapy clinical guidance

Informational (clinical trial dosing and starting recommendations that inform coverage rules)

Deferasirox starting dose guidance: Clinical studies support starting deferasirox at 20 mg/kg/day for transfusional iron overload; NTDT trials used lower starting doses (5 or 10 mg/kg/day) with dose-escalation criteria based on LIC and response.20 mg/kg/day starting dose (transfusional cases); 5–10 mg/kg/day (NTDT)

Doses below 20 mg/kg/day failed to provide consistent lowering of LIC and serum ferritin in transfusional trials.

Deferiprone dosing observed in trials: Deferiprone dosing in trials ranged approximately 35–99 mg/kg/day; success in pooled analysis defined by ≥20% decline in serum ferritin within one year.35–99 mg/kg/day (trial dosing)

Clinical trial dosing provided as informational guidance only for coverage decisions.

Continuation Therapy and Dose Adjustments

Continuation therapy

Re-authorization requirements

Re-authorization documentation: Re-authorization may be approved up to 12 months when drug-specific coverage criteria are met and chart notes document a reduction in serum ferritin levels below baseline.Reduction in serum ferritin vs baseline

Authorization duration and re-authorization follow pharmacy benefit management rules.

Continuation and dosing adjustments

Continuation and dose-adjustment rules used in open-label and extension studies (informational to coverage decisions)

Dose escalation rule: Doses could be increased after 6 months if LIC >7 mg Fe/g dw and LIC reduction from baseline <15%; Study 6 assigned starting doses by LIC (20 mg/kg/day for LIC >15; 10 mg/kg/day for LIC 3–15; observation if LIC <3).LIC >7 mg Fe/g dw and LIC reduction <15%

Step Therapy Requirements

Step	Requirement	Failure criteria
1	Trial of the generic formulation is required before approval of a branded deferasirox product (Exjade, Jadenu, Jadenu Sprinkle).	Inadequate response after 3 months of treatment with the generic product or intolerance to the generic product.

Step	Requirement	Failure criteria
1	Trial with generic deferiprone is required before coverage of Ferriprox (branded deferiprone).	Failure to tolerate or inadequate response after 3 months of treatment with generic deferiprone.

Site of Care

Note

Pharmacy‑benefit (outpatient) management

This policy is managed through the pharmacy benefit and applies to outpatient pharmacy dispensing.

Definitions

Chelation / Iron chelating agents

DefinitionDrugs that bind iron allowing its excretion in urine or feces to reduce iron overload from transfusions (iron chelating agents).

PurposeUsed to remove excess iron deposited in organs from chronic transfusions to prevent organ damage and reduce mortality.

Common settingsIndicated for transfusion-dependent conditions such as thalassemia major, sickle cell disease, aplastic anemia, MDS, and other chronic anemias requiring regular transfusions.

Serum ferritin (definition & role)

DefinitionSerum ferritin is the laboratory parameter most often used to assess total body iron burden and to monitor response to chelation therapy.

Clinical interpretationSustained ferritin > 2,500 mcg/L is associated with organ toxicity and higher cardiac risk; even levels around 1,000 mcg/L may indicate increased risk.

Background

Chronic, long‑term blood transfusions lead to progressive iron accumulation in organs such as the liver, heart, and endocrine glands. Untreated iron overload increases the risk of organ damage and mortality. Iron chelation therapy binds excess iron to facilitate excretion and is used to reduce body iron burden; serum ferritin is commonly used to assess total body iron and monitor response to therapy. Clinical trial and safety data referenced in this policy support chelation to prevent organ toxicity and reduce morbidity in transfusion‑dependent and certain non‑transfusion‑dependent patients.

OpenPayer

Oral Iron Chelating Agents (coverage criteria for deferasirox and deferiprone)

Coverage Criteria for Oral Iron Chelators

Coding and Thresholds

Provider Actions, Prior Authorization, and Documentation

Initial Therapy Criteria and Clinical Guidance

Continuation Therapy and Dose Adjustments

Step Therapy Requirements

Site of Care

Definitions

Background